✦ LIBER ✦

Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study

✍ Scribed by Carmen D. Schweighofer, Armin Tuchscherer, Sabine Sperka, Thorsten Meyer, Benno Rattel, Sandra Stein, Semra Ismail, Thomas Elter, Peter Staib, Marcel Reiser, Michael Hallek

Book ID: 118781431
Publisher: Springer-Verlag
Year: 2012
Tongue: English
Weight: 325 KB
Volume: 61
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-012-1362-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I/II study of 2-chloro-2′-deoxyade

Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin’s lymphoma

✍ Van Den Neste, E; Louviaux, I; Michaux, J L; Delannoy, A; Michaux, L; Sonet, A; 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 100 KB

Activity and safety of crizotinib in pat

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

✍ D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella- 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 310 KB